Home » Stocks » IMRN

Immuron Limited (IMRN)

Stock Price: $5.37 USD -0.22 (-3.94%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 33.00M
Revenue (ttm) 1.74M
Net Income (ttm) -2.02M
Shares Out 5.60M
EPS (ttm) -1.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $5.37
Previous Close $5.59
Change ($) -0.22
Change (%) -3.94%
Day's Open 5.62
Day's Range 5.35 - 5.65
Day's Volume 49,951
52-Week Range 1.81 - 28.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutic...

3 months ago - GlobeNewsWire

MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics...

4 months ago - GlobeNewsWire

Key Points

6 months ago - GlobeNewsWire

MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing ora...

8 months ago - GlobeNewsWire

Shares of Australian biopharma IMMURON LTD/S ADR (NASDAQ: IMRN) were rallying for the second day in a row Tuesday following an announcement concerning a potential COVID-19 treatment option.

8 months ago - Benzinga

Shares of Immuron Ltd. IMRN, +56.58% nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a registered d...

8 months ago - Market Watch

Immuron Ltd. (NASDAQ: IMRN) continued its winning streak on Tuesday after the company announced that its IMM-124E has demonstrated neutralizing activity against the severe acute respiratory syndrome cor...

8 months ago - 24/7 Wall Street

MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeut...

8 months ago - GlobeNewsWire

MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeut...

8 months ago - GlobeNewsWire

The day traders are back at it, chasing stocks on news with very few thoughts about what the fundamentals may be if the good news pans out.

10 months ago - 24/7 Wall Street

The U.S.-listed shares of of Immuron Ltd. IMRN, 1,152.32% skyrocketed nearly 10-fold on massive volume in afternoon trading Tuesday

10 months ago - Market Watch

Shares of Australian biopharma IMMURON LTD/S ADR (NASDAQ: IMRN) are on a roll Tuesday on the back of financing deal for one of its pipeline assets.

10 months ago - Benzinga

MELBOURNE, Australia, April 28, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeu...

11 months ago - GlobeNewsWire

MELBOURNE, Australia, March 25, 2020 (GLOBE NEWSWIRE) -- The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the Comp...

1 year ago - GlobeNewsWire

Key Highlights:

1 year ago - GlobeNewsWire

MELBOURNE, Australia, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeut...

1 year ago - GlobeNewsWire

Key Highlights:

1 year ago - GlobeNewsWire

Shares of thinly traded nano-cap biotech IMMURON LTD/S ADR (NASDAQ: IMRN) were off to a flying start Wednesday morning.

1 year ago - Benzinga

Shares of Australian nano-cap biotech Immuron (NASDAQ: IMRN) rose sharply Wednesday on roughly 250 times average volume.

1 year ago - Benzinga

About IMRN

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alc... [Read more...]

Industry
Biotechnology
Founded
1994
Stock Exchange
NASDAQ
Ticker Symbol
IMRN
Full Company Profile

Financial Performance

In 2020, Immuron's revenue was 2.52 million, an increase of 5.49% compared to the previous year's 2.39 million. Losses were -2.93 million, -37.14% less than in 2019.

Financial numbers in millions AUD.
Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Immuron is 6.41, which is an increase of 19.37% from the latest price.

Price Target
$6.41
(19.37% upside)